 | | Vol. 11.24 – 23 June, 2022 |
| |
|
|
| Treatment with MRX-2843, a first-in-class MERTK kinase inhibitor, re-sensitized GAS6-treated NSCLC cells to osimertinib.
[Journal of Clinical Investigation] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators defined a ‘distal’ differentiation approach to generate alveolar organoids from the same source for the derivation of airway organoids.
[Cell Discovery] |
|
|
|
| The authors confirmed the role of hypoxia-inducible factor-1α (HIF-1α) in arsenic-induced mitochondrial damage, and the effect of HIF-1α small interfering RNA on sodium arsenite-induced glycolysis in human bronchial epithelial cells was examined.
[Biological Trace Element Research] |
| |
|
|
| Researchers evaluated the activity of CC-115, a potent DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR) dual blocker, in different human NSCLC cells.
[Cell Death Discovery] |
|
|
|
| To identify novel genes that modulate the response to platinum-based therapy, investigators performed a genome-wide high-throughput ribonucleic acid interference screen via transfection of human lung cancer cells with a viral short hairpin RNA library.
[Scientific Reports] |
|
|
|
| Scientists systematically analyzed expression signatures of all 48 human ABC transporters in samples from 8562 patients across 14 different cancer types.
[Journal of Cancer Research and Clinical Oncology] |
|
|
|
|
| The authors discuss inhibition of BRAF and its downstream effector MEK which constitutes a therapeutic strategy for a subset of patients with NSCLC and is associated with clinical benefit.
[Clinical and Translational Oncology] |
|
|
|
|
| Cullinan Oncology, Inc. announced the completion of its agreement with Taiho Pharmaceutical Co., Ltd. to collaborate on the US development of CLN-081/TAS6417, an irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with NSCLC.
[Cullinan Oncology, Inc.] |
|
|
|
| BioKey, ABVC’s wholly-owned subsidiary, has entered into a Clinical Development Service Agreement with Rgene to guide three Rgene drug products.
[ABVC Biopharma, Inc. (Globe Newswire, Inc.)] |
|
|
|
| The US FDA issued a marketing denial order to JUUL Labs, Inc. for all of their products currently marketed in the US.
[FDA] |
|
|
|
|
| December 3 – 7, 2022
Washington, DC, United States |
|
|
|
|
|
| | Pennsylvania State University – State College, Pennsylvania, United States |
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
| | Washington University School of Medicine – St. Louis, Missouri, United States |
|
|
|
| | The Ohio State University Comprehensive Cancer Center – Columbus, Ohio, United States |
|
|
|
| | University of Bristol – Bristol, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
